Spruce Biosciences
SPRB
37 hedge funds and large institutions have $94.4M invested in Spruce Biosciences in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 5 closing their positions.
31% more capital invested
Capital invested by funds: $72M → $94.4M (+$22.4M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less funds holding
Funds holding: 38 → 37 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.41M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$761K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$346K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$163K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$73.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.98M |
| 2 |
AC
Armistice Capital
New York
|
-$1.27M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$924K |
| 4 |
Bank of New York Mellon
New York
|
-$201K |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$183K |
SPRB Hedge Fund Activity: Q4 2023 in Review
37 of the 6,864 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q4 2023, worth a combined $94.4M — up 31% from $72M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SPRB and 4 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 8 added.
The largest buyer was AIGH Capital Management, adding an estimated $1.41M. The largest seller was Verition Fund Management, exiting entirely with an estimated $2.98M sold.
- 37 institutional investors held Spruce Biosciences (SPRB) as of Q4 2023, down from 38 in Q3 2023.
- Funds reported $94.4M of Spruce Biosciences stock for Q4 2023, up 31% quarter-over-quarter.
- 4 funds opened new Spruce Biosciences positions in Q4 2023 and 5 closed out, a net change of -1 holder.
- The largest Spruce Biosciences buyer in Q4 2023 was AIGH Capital Management, an estimated $1.41M added.
- The largest Spruce Biosciences seller in Q4 2023 was Verition Fund Management, an estimated $2.98M sold.
Based on aggregated 13F filings for Q4 2023.